GleamWall
中文EN

AIDX 20/20 Biolabs, Inc.

Services-Testing Laboratories · Nasdaq · SEC CIK 1139685 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin29.7%
Operating margin-249.2%
Net margin-317.8%
FCF margin—
EBITDA margin-246.8%

Returns

ROE-1,768.6%
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets56.8%
Debt / equity0.00x
Current ratio1.62x
Interest coverage-7.51x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$380,216$730,571$353,375$538,274$417,979$535,060$553,820
Cost of revenue$283,343$425,844$290,491$407,857$272,913$371,796$388,025
Gross profit$96,873$304,727$62,884$130,417$145,066$163,264$165,795
R&D expense$123,385$257,632$153,482$130,554$131,060$194,124$136,831
SG&A expense$1.36M$1.29M$1.35M$912,709$814,179$814,811$801,144
Operating income-$1.39M-$1.24M-$1.44M-$912,846-$800,173-$845,671-$772,180
Interest expense-$1$272,245$267,008$124,985$29,547$935$740
Net income-$1.38M-$1.51M-$2.17M-$1.31M-$825,539-$840,933-$764,577
EBITDA-$1.38M-$1.23M-$1.43M-$898,332-$785,550-$831,009-$754,355
EPS (basic)-0.12-0.26-0.28—-0.17-0.17-0.16
EPS (diluted)-0.12-0.26-0.28—-0.17-0.17-0.16
Weighted avg. shares (diluted)12.96M10.79M7.66M—4.85M4.82M4.82M
Balance sheet
Cash & equivalents$3.63M$4.55M$4.22M$1.03M$1.14M$1.02M$1.56M
Receivables$173,985$291,486$201,481$199,954———
Inventory$102,568$111,036$104,523$116,217———
Current assets$4.03M$5.08M$4.70M$1.47M———
PP&E, net$24,525$33,700$45,187$56,677———
Intangibles$205,168$205,985$206,801$202,264———
Total assets$5.02M$6.12M$5.80M$4.14M———
Current liabilities$2.49M$2.55M$2.58M$2.46M———
Total liabilities$2.85M$2.96M$3.05M$4.16M———
Shareholders' equity$611,196$1.62M$2.55M-$19,225$108,457$351,610$1.06M
Shares outstanding13.37M12.25M10.44M5.44M———
Cash flow statement
Operating cash flow-$912,429-$605,460-$1.29M-$511,667-$385,655-$534,105-$488,293
Investing cash flow$0-$7,500-$5,354————
Financing cash flow$0$940,001$4.49M$392,799$506,561$0$262,338
Depreciation & amortization$9,175$11,487$12,306$14,514$14,623$14,662$17,825
Stock-based compensation$210,397$371,300$128,440$127,230$129,650$129,650$259,300

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.